The Alzheimer’s therapeutics and diagnostics market is expected to progress at a CAGR of 7.78% during the years 2019-2027.

Introduction to market

The market is driven by the rise in the number of Alzheimer’s cases and the growing demand for personalized drugs and affordable diagnostics tests. However, the stringent regulations for the development of drugs and clinical trials are hindering the growth of the Alzheimer’s Disease Therapeutics and Diagnostics Market globally. The high cost of therapies used for the treatment of Alzheimer’s disease also contributes to the same. A key challenge in the growth of the global Alzheimer’s disease treatment and diagnostics market is the shortage of skilled medical practitioners across the developing countries. In addition, the lack of awareness regarding new therapies that are used for the treatment of the Alzheimer’s disease acts as a significant growth challenge for the global Alzheimer’s disease treatment and diagnostics market over the forecast period.

Browse full research report with TOC on " Alzheimer’s Therapeutics and Diagnostics Market Analysis By Therapeutics and Diagnostics (Therapeutics (Drugs - Market Drugs and Pipeline Drugs, Disease Stage - Late Stage: Severe AD and Early/Middle Stage: Mild to Moderate AD, Prodromal Stage, Generic and Branded), by Diagnostics (Lumbar Puncture Test, Positron Emission Tomography, Electroencephalography, Magnetic Resonance Imaging, Computed Tomography, Other Diagnostics)) and Geography”

Request Free Sample Now: https://www.tritonmarketresearch.com/reports/alzheimer%E2%80%99s-disease-therapeutics-and-diagnostic-market-#request-free-sample

According to Triton Market research, the Asia Pacific region held the largest share amongst the various regional markets

Europe, Asia Pacific and North America and rest of the world are the regional segments of the global Alzheimer’s therapeutic and diagnostic market. Presently, the Asia Pacific region is holding the reign globally. With the government investment in the R&D for drugs and diagnostic test, which is further supported by the increasing population and the large proportion of people aged above 65 years in the regions, the demand for personalized drugs is expected to witness a boom for the Alzheimer’s therapeutic and diagnostic market in this region.

The Alzheimer’s therapeutics & diagnostics market in Asia-Pacific is the fastest growing market globally. The primary driver of the Alzheimer’s disease therapeutics & diagnostics market in China is the burgeoning rise in the population of the country, which is thereby increasing the aging population. This aging population is vulnerable to diseases like dementia, thus causing a rise in its prevalence across the country, mainly in the semi-urban and rural provinces. According to the Ministry of Health, China is one of the leading countries in terms of the number of individuals affected by dementia, which accounts for around 20% of the dementia cases globally.

The major companies operating in the Alzheimer’s Therapeutics and Diagnostics Market are:

• BAXTER INTERNATIONAL, INC.
• ABBVIE, INC.
• DIAGENIC ASA
• AMARANTUS BIOSCIENCE HOLDINGS, INC.
• PIRAMAL ENTERPRISES, LTD.
• DIAGENIC ASA
• SIEMENS MEDICAL SOLUTIONS
• BIOGEN, INC.
• GE HEALTHCARE
• SUN PHARMA
• AXON NEUROSCIENCE SE

Find more research reports on Lifescience Industry, by Triton Market Research:

• Biochips Market 2019-2027
• Healthcare Analytics Market 2019-2027
• Artificial Intelligence (AI) in Healthcare Market 2019-2027